In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period

INTRODUCTION: SB12 is a biosimilar to eculizumab reference product [Soliris(TM) (Soliris is a trademark of Alexion Pharmaceuticals, Inc.)] that acts as a C5 complement protein inhibitor. The infusion stability of in-use (diluted) SB12 outside the conditions stated in the reference product’s label is...

Descripción completa

Detalles Bibliográficos
Autores principales: Tak, Minji, Jeong, Hawon, Yun, Jihoon, Kim, Jihyun, Kim, Soyeon, Lee, Yoonsook, Park, Su Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676327/
https://www.ncbi.nlm.nih.gov/pubmed/37606749
http://dx.doi.org/10.1007/s40268-023-00433-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676327/
https://www.ncbi.nlm.nih.gov/pubmed/37606749
http://dx.doi.org/10.1007/s40268-023-00433-7

Ejemplares similares